Thomas Mac Lennan MacDonald

List of Publications by Year
in descending order

86	3,120	257101	168136
papers	citations	24	53
		h-index	g-index

91	91	91	4060
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet, The, 2015, 386, 2059-2068.	6.3	904
2	Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes and Endocrinology,the, 2018, 6, 464-475.	5.5	206
3	Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet, The, 2020, 396, 1745-1757.	6.3	192
4	Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ, The, 2021, 372, n135.	3.0	102
5	Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes and Endocrinology,the, 2016, 4, 136-147.	5.5	99
6	Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open, 2014, 4, e005354-e005354.	0.8	81
7	Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double€Blind Randomized Controlled Trial. Journal of the American Heart Association, 2017, 6, .	1.6	74
8	Association between cardiovascular events and sodium-containing effervescent, dispersible, and soluble drugs: nested case-control study. BMJ, The, 2013, 347, f6954-f6954.	3.0	70
9	Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study. BMJ Open, 2016, 6, e013774.	0.8	70
10	Effectiveness of Statins on Total Cholesterol and Cardiovascular Disease and All-cause Mortality in Osteoarthritis and Rheumatoid Arthritis. Journal of Rheumatology, 2012, 39, 32-40.	1.0	65
11	Home Blood Pressure Monitoring. European Cardiology Review, 2015, 10, 95.	0.7	64
12	Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study. BMJ Open, 2016, 6, e010313.	0.8	58
13	Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). European Heart Journal, 2017, 38, ehw387.	1.0	58
14	Irbesartan Reduces QT Dispersion in Hypertensive Individuals. Hypertension, 1999, 33, 713-718.	1.3	52
15	Use and adherence to beta-blockers for secondary prevention of myocardial infarction: who is not getting the treatment?. Pharmacoepidemiology and Drug Safety, 2004, 13, 761-766.	0.9	46
16	Exaggerated Exercise Blood Pressure Response and Future Cardiovascular Disease. Journal of Clinical Hypertension, 2015, 17, 837-844.	1.0	46
17	Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. British Journal of Clinical Pharmacology, 2017, 83, 653-663.	1.1	44
18	Up-titration of allopurinol in patients with gout. Seminars in Arthritis and Rheumatism, 2014, 44, 25-30.	1.6	42

#	ARTICLE	IF	CITATIONS
19	Acid‐suppression medications and bacterial gastroenteritis: a population‐based cohort study. British Journal of Clinical Pharmacology, 2017, 83, 1298-1308.	1.1	33
20	Does offering an incentive payment improve recruitment to clinical trials and increase the proportion of socially deprived and elderly participants?. Trials, 2015, 16, 80.	0.7	32
21	The multiple propensity score for analysis of dose-response relationships in drug safety studies. Pharmacoepidemiology and Drug Safety, 2001, 10, 105-111.	0.9	30
22	Learning from remote decentralised clinical trial experiences: A qualitative analysis of interviews with trial personnel, patient representatives and other stakeholders. British Journal of Clinical Pharmacology, 2022, 88, 1031-1042.	1.1	30
23	From Inception to ConcePTION: Genesis of a Network to Support Better Monitoring and Communication of Medication Safety During Pregnancy and Breastfeeding. Clinical Pharmacology and Therapeutics, 2022, 111, 321-331.	2.3	30
24	Is there an Interaction between the Cardiovascular Protective Effects of Low-Dose Aspirin and Ibuprofen?. Basic and Clinical Pharmacology and Toxicology, 2006, 98, 275-280.	1.2	29
25	A systematic review of methods used to conduct decentralised clinical trials. British Journal of Clinical Pharmacology, 2022, 88, 2843-2862.	1.1	28
26	Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO. Journal of Hypertension, 2010, 28, 170-177.	0.3	27
27	Electronic case report forms and electronic data capture within clinical trials and pharmacoepidemiology. British Journal of Clinical Pharmacology, 2017, 83, 1880-1895.	1.1	27
28	Tolerability of Topical NSAIDs in the Elderly. Drugs and Aging, 1996, 9, 101-108.	1.3	26
29	Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis. Arthritis Research and Therapy, 2008, 10, S3.	1.6	25
30	Cardiovascular Safety of Prucalopride in Patients with Chronic Constipation: A Multinational Population-Based Cohort Study. Drug Safety, 2019, 42, 1179-1190.	1.4	25
31	Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom. British Journal of Clinical Pharmacology, 2008, 65, 775-786.	1.1	24
32	Navigating the shoals in hypertension: discovery and guidance. BMJ, The, 2012, 344, d8218-d8218.	3.0	23
33	Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard care versus celecoxib outcome trial (SCOT). BMJ Open, 2013, 3, e002295.	0.8	22
34	Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial. Journal of Hypertension, 2008, 26, 1695-1702.	0.3	21
35	Treatment of osteoarthritis in hypertensive patients. Expert Opinion on Pharmacotherapy, 2010, 11, 393-403.	0.9	20
36	Investigating Real‐World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records. Clinical Pharmacology and Therapeutics, 2018, 103, 281-286.	2.3	19

#	ARTICLE	IF	CITATIONS
37	Chronotherapy in hypertension: the devil is in the details. European Heart Journal, 2020, 41, 1606-1607.	1.0	18
38	The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 study. Atherosclerosis Supplements, 2020, 42, e15-e24.	1.2	18
39	Isolated diastolic heart failure as a cause of breathlessness in the community: the Arbroath study. European Journal of Heart Failure, 2001, 3, 243-248.	2.9	17
40	The Tayside Medicines Monitoring Unit (MEMO). , 0, , 323-336.		17
41	Nonadherence with ACE Inhibitors Is Common and Can Be Detected in Clinical Practice by Routine Serum ACE Activity. Congestive Heart Failure, 2001, 7, 43-50.	2.0	16
42	The Treatment In Morning versus Evening (TIME) study: analysis of recruitment, follow-up and retention rates post-recruitment. Trials, 2017, 18, 557.	0.7	16
43	The Tayside Medicines Monitoring Unit (MEMO). , 0, , 361-374.		14
44	Study protocol for statin web-based investigation of side effects (StatinWISE): a series of randomised controlled N-of-1 trials comparing atorvastatin and placebo in UK primary care. BMJ Open, 2017, 7, e016604.	0.8	14
45	The effect of indapamide <i>vs</i>. bendroflumethiazide for primary hypertension: a systematic review. British Journal of Clinical Pharmacology, 2019, 85, 285-303.	1.1	14
46	Cardiovascular safety of lumiracoxib: a meta-analysis of randomised controlled trials in patients with osteoarthritis. European Journal of Clinical Pharmacology, 2013, 69, 133-141.	0.8	13
47	Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension. BMJ Open, 2015, 5, e008951.	0.8	13
48	Identifying poor adherence to antihypertensive medications in patients with resistant hypertension. British Journal of Clinical Pharmacology, 2019, 85, 5-7.	1.1	12
49	Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The Netherlands. Pharmacoepidemiology and Drug Safety, 2020, 29, 296-305.	0.9	12
50	Cluster randomized trials of prescription medicines or prescribing policy: public and general practitioner opinions in Scotland. British Journal of Clinical Pharmacology, 2012, 74, 354-361.	1.1	10
51	Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trial: FigureÂ1. BMJ Open, 2015, 5, e007645.	0.8	10
52	The effect of changes to GOLD severity stage on long term morbidity and mortality in COPD. Respiratory Research, 2018, 19, 249.	1.4	10
53	Adverse events and overall health and well-being after COVID-19 vaccination: interim results from the VAC4COVID cohort safety study. BMJ Open, 2022, 12, e060583.	0.8	10
54	Impact of EU regulatory label changes for diclofenac in people with cardiovascular disease in four countries: Interrupted time series regression analysis. British Journal of Clinical Pharmacology, 2021, 87, 1129-1140.	1.1	9

#	ARTICLE	IF	CITATIONS
55	Design and rationale of a nationwide screening analysis from the LIPIDOGRAM2015 and LIPIDOGEN2015 studies. Archives of Medical Science, 2020, 18, 604-616.	0.4	9
56	The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGRAM 2015 Study. Journal of Clinical Medicine, 2021, 10, 5656.	1.0	9
57	The Doctor-Patient Relationship and Prescribing Patterns. Pharmacoeconomics, 1999, 16, 599-603.	1.7	8
58	Comparison of single and combination diuretics on glucose tolerance (PATHWAY-3): protocol for a randomised double-blind trial in patients with essential hypertension. BMJ Open, 2015, 5, e008086.	0.8	7
59	Association between prior appendectomy and/or tonsillectomy in women and subsequent pregnancy rate: a cohort study. Fertility and Sterility, 2016, 106, 1150-1156.	0.5	7
60	Rationale and Design of the Genotype-Blinded Trial of Torasemide for the Treatment of Hypertension (BHF UMOD). American Journal of Hypertension, 2021, 34, 92-99.	1.0	7
61	Drug treatment discontinuation and achievement of target blood pressure and cholesterol in United Kingdom primary care. Current Medical Research and Opinion, 2007, 23, 2765-2774.	0.9	6
62	Home blood pressure monitors owned by participants in a large decentralised clinical trial in hypertension: the Treatment In Morning versus Evening (TIME) study. Journal of Human Hypertension, 2022, 36, 32-39.	1.0	6
63	Factors influencing home blood pressure monitor ownership in a large clinical trial. Journal of Human Hypertension, 2022, 36, 325-332.	1.0	6
64	The effect of statins on muscle symptoms in primary care: the StatinWISE series of 200 N-of-1 RCTs. Health Technology Assessment, 2021, 25, 1-62.	1.3	6
65	The pharmacokinetics of γ-glutamyl-l-dopa in normal and anephric rats and rats with glycerol-induced acute renal failure. British Journal of Pharmacology, 1990, 101, 301-306.	2.7	5
66	A novel drug management system in the Febuxostat versus Allopurinol Streamlined Trial: A description of a pharmacy system designed to supply medications directly to patients within a prospective multicenter randomised clinical trial. Clinical Trials, 2016, 13, 665-670.	0.7	5
67	Factors influencing participation and long-term commitment to self-monitoring of blood pressure in a large remote clinical trial: The treatment in morning versus evening (TIME) study. Journal of Human Hypertension, 2022, 36, 1099-1105.	1.0	5
68	Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study. Rheumatology International, 2022, 42, 261-271.	1.5	5
69	Ibuprofen and Paracetamol: Acceptably Safe for All?. Drug Safety, 2018, 41, 999-1001.	1.4	4
70	When innovation outpaces regulations: The legal challenges for direct-to-patient supply of investigational medicinal products. British Journal of Clinical Pharmacology, 2022, 88, 1115-1142.	1.1	4
71	Pharmacoepidemiological research at the Medicines Monitoring Unit, Scotland: data protection and confidentiality. Pharmacoepidemiology and Drug Safety, 2001, 10, 669-673.	0.9	4
72	Evaluating Diuretics in Normal Care (EVIDENCE): protocol of a cluster randomised controlled equivalence trial of prescribing policy to compare the effectiveness of thiazide-type diuretics in hypertension. Trials, 2021, 22, 814.	0.7	4

#	ARTICLE	IF	CITATIONS
73	Channelling of SSRIs and SNRIs use in the Tayside population, Scotland. Pharmacoepidemiology and Drug Safety, 2007, 16, 859-866.	0.9	3
74	Does the provision of a DVD-based audio-visual presentation improve recruitment in a clinical trial? A randomised trial of DVD trial invitations. BMC Medical Research Methodology, 2019, 19, 24.	1.4	3
75	Cluster randomised trials of prescribing policy: an ethical approach to generating drug safety evidence? A discussion of the ethical application of a new research method. Trials, 2020, 21, 477.	0.7	3
76	Impact of EMA regulatory label changes on hydroxyzine initiation, discontinuation and switching to other medicines in Denmark, Scotland, England and the Netherlands: An interrupted time series regression analysis. Pharmacoepidemiology and Drug Safety, 2021, 30, 482-491.	0.9	3
77	MEMO in the UK. , 0, , 363-371.		2
78	Changes in prescribing rates of sodium-containing medications in the UK from 2009 to 2018: a cross-sectional study with interrupted time series analysis. BMJ Open, 2021, 11, e043566.	0.8	2
79	The effect of hip replacement on prescribing of NSAIDs, ulcer healing drugs and hospitalization—a matched cohort study. , 1999, 8, 423-431.		1
80	Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress. Biomarker Insights, 2022, 17, 117727192110667.	1.0	1
81	A European??s Perspective of COX-2 Drug Safety. Journal of Cardiovascular Pharmacology, 2006, 47, S92-S97.	0.8	0
82	The Authors Reply:. Kidney International, 2014, 85, 211.	2.6	0
83	Cardiovascular safety of febuxostat — Authors' reply. Lancet, The, 2021, 398, 955-956.	6.3	0
84	Protocol for assessment of sleep quality and duration in the Treatment In Morning versus Evening (TIME) study: a randomised controlled trial using online patient-reported outcome measures. BMJ Open, 2018, 8, e021890.	0.8	0
85	Evaluating Diuretics in Normal Care (EVIDENCE): a feasibility report of a pilot cluster randomised trial of prescribing policy in primary care to compare the effectiveness of thiazide-type diuretics in hypertension. Pilot and Feasibility Studies, 2022, 8, 62.	0.5	0
86	MEMO in the United Kingdom. , 0, , 333-340.		0